Suncoast Equity Management
NBIX icon

Suncoast Equity Management’s Neurocrine Biosciences NBIX Stock Holding History

Suncoast Equity Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$775K Buy
5,465
+110
+2% +$17.7K 0.1% 50
2026
Q2 		$903K Buy
5,355
+1,320
+33% +$196K 0.11% 47
2026
Q1 		$532K Sell
4,035
-1,050
-21% -$139K 0.06% 65
2025
Q4 		$721K Buy
+5,085
New +$737K 0.07% 61

Other funds holding NBIX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $61B AUM 26.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
IEQ Capital
IEQ Capital Foster City, California $23.5B AUM 29.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return

Suncoast Equity Management's NBIX Position: Q3 2026 in Review

Suncoast Equity Management increased its Neurocrine Biosciences (NBIX) stake by 2.1% in Q3 2026, buying an estimated $17.7K and bringing the position to 5,465 shares worth $775K. The position accounts for 0.1% of the portfolio, ranked #50.

Suncoast Equity Management first reported a position in NBIX in Q4 2025 and has held it in 4 quarters since. The position peaked at $903K in Q2 2026. 446 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Suncoast Equity Management held 5,465 shares of Neurocrine Biosciences worth $775K as of Q3 2026.
  • Suncoast Equity Management bought 110 Neurocrine Biosciences shares in Q3 2026, an estimated $17.7K.
  • Neurocrine Biosciences made up 0.1% of Suncoast Equity Management's portfolio in Q3 2026, its #50 holding.
  • Suncoast Equity Management first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 4 quarters since.
  • Suncoast Equity Management's Neurocrine Biosciences position peaked at $903K in Q2 2026.
  • 446 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Suncoast Equity Management's 13F filing for Q3 2026, filed 3 Nov 2026.